Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.
|Articles|September 7, 2021
Pharmacy Clinical Pearl of the Day: Psoriasis
Author(s)Saro Arakelians, PharmD
Psoriasis is a common, long-term chronic disease with no cure that goes through cycles, flaring for a few weeks or months, then going into remission.
Advertisement
Clinical Pearl of the Day: Psoriasis
Psoriasis is a skin disease that causes red, itchy, scaly patches, most commonly on the knees, elbows, trunk, and scalp.
Explanation:
- Psoriasis is a common, long-term chronic disease with no cure.
- It goes through cycles, flaring for a few weeks or months, then subsiding for a while or going into remission.
- Symptoms include: Red patches of skin covered with thick, silvery scales, small scaling spots (commonly seen in children), dry and cracked skin that may bleed or itch, burning or soreness, thickened and pitted or ridged nails, swollen and stiff joints.
- Types of psoriasis include plaque psoriasis, nail psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, psoriatic arthritis.
- Treatments include: corticosteroids, vitamin D analogues, retinoids, calcineurin inhibitors, salicylic acid, coal tar, Goeckerman therapy, and anthralin.
Reference:
Advertisement
Related to this article
In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.
Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.
Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.
A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.
Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Preparing Pharmacists for Psychedelic Medicine
2
Pneumonic Plague: What Pharmacists Need to Know About Treatment
3
Beyond Skin Clearance: What Litifilimab Could Mean for Cutaneous Lupus Care
4
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
5